Celon Pharma (8RP) Stock Overview
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
8RP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.72 |
| 52 Week High | zł6.57 |
| 52 Week Low | zł4.27 |
| Beta | 0.71 |
| 1 Month Change | -10.94% |
| 3 Month Change | 4.89% |
| 1 Year Change | -24.24% |
| 3 Year Change | 53.00% |
| 5 Year Change | -56.13% |
| Change since IPO | -52.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8RP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.9% | 1.1% | -0.3% |
| 1Y | -24.2% | 6.0% | -2.3% |
Return vs Industry: 8RP underperformed the German Pharmaceuticals industry which returned 3.1% over the past year.
Return vs Market: 8RP underperformed the German Market which returned -2.6% over the past year.
Price Volatility
| 8RP volatility | |
|---|---|
| 8RP Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DE Market | 14.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 8RP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8RP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 566 | Maciej Wieczorek | www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.
Celon Pharma S.A. Fundamentals Summary
| 8RP fundamental statistics | |
|---|---|
| Market cap | €265.42m |
| Earnings (TTM) | -€28.72m |
| Revenue (TTM) | €52.94m |
Is 8RP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8RP income statement (TTM) | |
|---|---|
| Revenue | zł225.60m |
| Cost of Revenue | zł71.47m |
| Gross Profit | zł154.13m |
| Other Expenses | zł276.52m |
| Earnings | -zł122.39m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 22, 2026
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 68.32% |
| Net Profit Margin | -54.25% |
| Debt/Equity Ratio | 0.1% |
How did 8RP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/17 09:46 |
| End of Day Share Price | 2026/03/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celon Pharma S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Vladimira Urbankova | Erste Group Bank AG |